Non-Small Cell Lung Cancer Market to Grow with a CAGR of 9.60% through 2028
Increase in the
incidence and prevalence of Non-Small Cell Lung Cancer and advancement in
diagnostics is expected to drive the Global Non-Small Cell Lung Cancer Market
growth in the forecast period, 2024-2028.
According to
TechSci Research report, “Non-Small Cell Lung Cancer Market – Global Industry
Size, Share, Trends, Competition Forecast & Opportunities, 2028”,
the Global Non-Small Cell Lung Cancer Market stood at USD 15.09 billion in 2022
and is anticipated to grow with a CAGR of 9.60% in the forecast period,
2024-2028. The awareness among individuals regarding Non-Small Cell Lung Cancer
has led to favorable market conditions for the global Non-Small Cell Lung
Cancer market. Several factors contribute to the growth of various Non-Small
Cell Lung Cancer products.
The market for
Non-Small Cell Lung Cancer (NSCLC) is significantly driven by the increasing
incidence of the disease, primarily caused by factors like smoking,
environmental pollution, and an aging population. Furthermore, the continuous
advancement of diagnostic technologies, such as CT scans, PET scans, and
molecular testing, has led to enhanced early detection rates, resulting in more
timely treatment and thus stimulating market growth. Additionally, the
evolution of innovative treatment approaches, including targeted therapies and
immunotherapies, has broadened the array of options accessible to NSCLC
patients, ultimately amplifying the demand within the market.
The existence of
sophisticated healthcare infrastructure, encompassing dedicated cancer centers
and specialized facilities, elevates the quality of patient care and treatment,
thereby propelling market expansion. Broader health insurance coverage
contributes to heightened accessibility and affordability of NSCLC treatments
for patients, fostering increased demand for healthcare services, which will
further fuel market growth.
In August 2023,
Bayer announced the initiation of a Phase III clinical trial of asundexian, an
oral factor XIa inhibitor, for the prevention of VTE in patients with atrial
fibrillation (AF). Asundexian has the potential to be a first-in-class oral
treatment for VTE prevention in patients with AF, who are at high risk of VTE
but cannot tolerate warfarin or other anticoagulants.
The
multidisciplinary approach to NSCLC treatment, involving various medical
specialists, ensures comprehensive and holistic care. This model enhances
treatment outcomes and sets a precedent for healthcare delivery in other
medical fields.
In today's
fast-paced world, NSCLC serves as a focal point for medical research and
innovation. The complexities of this disease have led to significant advances
in cancer treatment, including targeted therapies and immunotherapies. These
breakthroughs not only benefit NSCLC patients but also pave the way for
advancements in treating other types of cancer and various medical conditions. The
emphasis on early detection of NSCLC has driven the development of advanced
diagnostic technologies. These innovations, such as low-dose CT scans and
molecular testing, are not only vital for detecting NSCLC at earlier, more
treatable stages but also applicable to the early detection of other cancers
and diseases, potentially saving countless lives. NSCLC has played a pivotal
role in the advancement of precision medicine. Tailoring treatments to a
patient's unique genetic profile has become a standard practice in NSCLC care.
This approach is not only effective in managing NSCLC but also holds promise
for treating other diseases with targeted therapies. NSCLC has been at the
forefront of the immunotherapy revolution. Immunotherapies, including
PD-1/PD-L1 inhibitors, have shown remarkable success in NSCLC treatment. The
principles behind these therapies are now being applied to other types of
cancer, offering new hope to patients worldwide. The multidisciplinary approach
to NSCLC treatment, involving various medical specialists and support services,
sets a precedent for comprehensive healthcare. This patient-centered model
promotes collaboration among healthcare professionals and improves overall patient
care, setting a standard for healthcare delivery in our fast-paced world.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Non-Small Cell Lung Cancer Market”
Increased
initiatives have been undertaken to enlighten both the general public and
healthcare practitioners regarding the risks and symptoms associated with
NSCLC, as well as the critical significance of early detection. This heightened
awareness has resulted in more prompt diagnoses. Moreover, an array of
supportive services, encompassing psychological counseling, pain control, and
dietary guidance, has become essential elements of NSCLC care, significantly
enhancing the overall patient journey.
In recent times,
significant advancements in the development of targeted therapies for NSCLC.
These drugs are designed to specifically target cancer cells with certain
genetic mutations, offering more precise and effective treatment options. The
emergence of targeted therapies has improved treatment outcomes and prolonged
the lives of many NSCLC patients. Immunotherapies, particularly PD-1/PD-L1
inhibitors, have revolutionized NSCLC treatment. They work by enhancing the
body's immune system to recognize and attack cancer cells. In recent times,
immunotherapies have become a standard treatment option, offering durable
responses for some patients, even in advanced stages of the disease. NSCLC has
been at the forefront of personalized medicine. Genetic profiling of tumors
allows oncologists to tailor treatment plans to the unique genetic
characteristics of each patient's cancer. This approach maximizes treatment
efficacy while minimizing side effects. However, Late Diagnosis such as NSCLC
is often diagnosed at an advanced stage when treatment options are limited may
hinder market growth. Moreover, challenges related to Immunotherapy Response
Variability and Limited Access to Healthcare may pose obstacles to the Non-Small
Cell Lung Cancer market in the near future.
The Global Non-Small
Cell Lung Cancer Market is segmented into type, treatment, drug type, end-user,
regional distribution, and company.
Based on its type,
the Non-Small Cell Lung Cancer, adenocarcinoma has emerged as the dominant
player. Factors such as changing smoking patterns, environmental influences,
advances in diagnostics, and the availability of targeted therapies have all
contributed to its prominence within the global NSCLC market. As research
continues to advance and our understanding of adenocarcinoma deepens, we can
expect even more tailored and effective treatments for this prevalent subtype
of lung cancer. Advancements in diagnostic techniques, particularly the
widespread adoption of computed tomography (CT) scans and the development of
molecular testing, have facilitated the early detection of adenocarcinoma. This
early detection allows for more timely intervention and potentially better
treatment outcomes. One of the most significant factors contributing to
adenocarcinoma's dominance is the availability of targeted therapies.
Adenocarcinoma is often associated with specific genetic mutations, such as
EGFR and ALK. Targeted therapies that directly address these mutations have
shown remarkable efficacy in treating adenocarcinoma patients, further
solidifying its position in the NSCLC market. These factors are expected to
drive the growth of this segment.
Based on region,
North America segment is expected to grow during the forecast
period. North America boasts advanced healthcare infrastructure,
with state-of-the-art hospitals, research institutions, and cancer centers that
specialize in NSCLC diagnosis and treatment. Historically, high smoking rates
in North America have contributed to a significant NSCLC burden. This has
resulted in a well-established framework for NSCLC diagnosis and treatment.
North America has been an early adopter of innovative NSCLC therapies,
including targeted therapies and immunotherapies, leading to better treatment
outcomes. The region hosts numerous clinical trials, attracting both domestic
and international patients seeking access to cutting-edge treatments and
therapies. The presence of comprehensive health insurance systems in North
America facilitates access to expensive NSCLC treatments and ensures a higher
standard of care for patients. North America is home to major pharmaceutical
companies that develop and market NSCLC drugs, further solidifying its
dominance.
The Asia-Pacific
market is poised to be the fastest-growing market, offering lucrative growth
opportunities for Non-Small Cell Lung Cancer players during the forecast
period. Factors such as Rising smoking rates and changing lifestyles in some
APAC countries contribute to an increased NSCLC incidence. Many APAC countries
are investing heavily in healthcare infrastructure development, including the
establishment of modern cancer centers and research facilities. As the region's
economies grow, more patients gain access to innovative NSCLC therapies and
treatment options. The region is becoming a hub for clinical trials, attracting
global pharmaceutical companies and researchers, which accelerates the
development of new treatments. Some APAC governments are implementing policies
and programs to improve cancer awareness, early detection, and access to
treatment. Expanding health insurance coverage in APAC countries is making
NSCLC treatments more accessible and affordable for patients.
Major companies
operating in Global Non-Small Cell Lung Cancer Market are:
- Bayar Healthcare AG
- Eli Lilly & Co.
- Biogen Inc
- Merck & Co
- AbbVie Inc
- AstraZeneca PLC
- Novartis AG
- Pfizer Inc
- Avid Bioservices Inc
- Blueprint Medicines Company
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“The Advancements
in Diagnostics and increasing prevalence are key drivers of the Non-Small Cell
Lung Cancer market. In recent years, The development of innovative treatment
modalities, including targeted therapies and immunotherapies, has expanded the
range of options available to NSCLC patients, boosting market demand. Moreover,
the growing consumer emphasis on preventative healthcare products has enhanced
production and marketing efforts. To meet the demands of the market,
manufacturers are increasingly incorporating cutting-edge technologies with
high production efficiency. Rising consumer acceptance and continuous product
innovation will further ensure the growth of the Non-Small Cell Lung Cancer and
supplements market in the coming years.,” said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based management consulting firm.
“Non-Small
Cell Lung Cancer Market – Global Industry Size, Share, Trends, Opportunity,
& Forecast 2018-2028 Segmented By Type (Adenocarcinoma, Squamous Cell
Carcinoma, Large Cell Carcinoma), By
Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, Targeted
Therapy Drugs), By Drug Class (Angiogenesis Inhibitor, Epidermal Growth Factor
Receptor Blocker, Kinase Inhibitor, Microtubule Stabilizer, Folate
Antimetabolites, PD-1/ PD-L1 Inhibitor), By End-User (Hospitals & Clinics,
Others), By Region & Competition”, has evaluated
the future growth potential of Global Non-Small Cell Lung Cancer Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Non-Small Cell Lung Cancer Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com